Alglucerase
- Atc Codes:A16AB01
- CAS Codes:143003-46-7
- PHARMGKB ID:143003-46-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Ceredase.
Drug combinations
Chemistry
Alglucerase: C~2532~H~3854~N~672~O~711~S~16~ (protein moiety). 59,300 (SDS-PAGE determined). A modified form of human placental tissue β-glucocerebrosidase (β-D-glucosyl-N-acylsphingosine glucohydrolase). It is a monomeric glycoprotein of 497 aa; approximately 12% of the glycoprotein consists of N-linked carbohydrate chains of the complex and high mannose type. (1) Glucosylceramidase (human placenta isoenzyme protein moiety reduced); (2) Glucosylceramidase (human placenta isoenzyme protein moiety reduced). CAS-143003-46-7 (1992).
Pharmacologic Category
Enzymes. (ATC-Code: A16AB01).
Mechanism of action
Alglucerase is a modified form of glucocerebrosidase enzyme, prepared from human placental tissue. Glucocerebrosidase catalyzes the hydrolysis of glucocerebroside to glucose and ceramide.
Therapeutic use
Replacement therapy for Gaucher’s disease (type 1).
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation.
Warnings and precautions
Derived from pooled human placental tissue that may contain agents of some viral diseases. Hypersensitivity reactions may occur (patients who develop IgG antibodies may be at a higher risk). May cause early virilization in males <10 years of age. Use with caution in androgen-sensitive malignancies.